What it's for (Indications)
- Orlistat is indicated for long-term weight management, including weight loss and weight maintenance, in adults and adolescents aged 12 years and older.
- It is specifically recommended for individuals who are overweight (Body Mass Index [BMI] ≥ 27 kg/m²) with associated comorbidities, or obese (BMI ≥ 30 kg/m²).
- This medication should be used in conjunction with a nutritionally balanced, reduced-calorie diet and increased physical activity.
- Orlistat aids in achieving significant weight loss and helps prevent weight regain following initial weight reduction.
- Its efficacy is maximized when integrated into a comprehensive weight management program that emphasizes lifestyle modifications.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults and adolescents 12 years of age and older, the recommended dose of prescription-strength orlistat (120 mg) is one capsule three times a day. Each dose should be taken immediately before, during, or up to one hour after each main meal that contains fat. If a meal is missed or contains no fat, the dose of orlistat should be omitted. It is crucial for patients to adhere to a nutritionally balanced, reduced-calorie diet in which approximately 30% of total calories are derived from fat. The daily intake of fat, carbohydrates, and protein should be evenly distributed over the three main meals. A daily multivitamin supplement containing fat-soluble vitamins (A, D, E, and K) should be taken at bedtime or at least 2 hours before or after orlistat administration to prevent potential vitamin deficiencies. |
Safety & Warnings
Common Side Effects
- Common side effects associated with orlistat are primarily gastrointestinal and dose-dependent, often diminishing with continued treatment and reduced dietary fat intake.
- These include oily spotting, flatulence with discharge, fecal urgency, fatty or oily stools (steatorrhea), increased defecation, abdominal pain or discomfort, nausea, and vomiting.
- Less common but serious adverse effects include severe liver injury (rarely leading to liver failure or transplantation), and acute oxalate nephropathy potentially resulting in renal failure.
- Other reported side effects encompass headache, menstrual irregularities, anxiety, influenza-like symptoms, and respiratory tract infections.
- Reduced absorption of fat-soluble vitamins (A, D, E, K) can occur, necessitating supplementation.
Serious Warnings
- Black Box Warning: Orlistat does not carry a formal FDA Black Box Warning. However, serious safety information regarding potential adverse effects warrants significant attention and is detailed below in a 'Serious Warnings' section, reflecting high-risk factors that prescribers and patients must be aware of. **Serious Warnings**: * **Potential for Severe Liver Injury**: While rare, severe liver injury, including cases leading to liver failure and requiring transplantation, has been reported in postmarketing surveillance of orlistat. Patients should be advised to discontinue orlistat and seek immediate medical attention if they develop signs or symptoms suggestive of liver dysfunction, such as pruritus, yellow eyes or skin (jaundice), dark urine, light-colored stools, anorexia, or severe upper abdominal pain. Prescribers should exercise caution in patients with pre-existing liver disease and monitor for such symptoms. * **Acute Kidney Injury (Oxalate Nephropathy)**: Cases of acute oxalate nephropathy, sometimes leading to renal failure, have been reported in patients treated with orlistat. This risk may be increased in patients with underlying chronic kidney disease or other risk factors for oxalate nephropathy. It is important to ensure adequate hydration and monitor renal function, particularly in susceptible individuals. Patients should be advised to report any signs of kidney problems, such as decreased urine output or swelling. * **Malabsorption of Fat-Soluble Vitamins**: Orlistat significantly reduces the absorption of fat-soluble vitamins (A, D, E, and K) and beta-carotene. To prevent potential deficiencies, patients should be counselled to take a daily multivitamin supplement containing these vitamins at least two hours before or after the administration of orlistat, or at bedtime. Consistent monitoring for signs of vitamin deficiency may be warranted, especially during prolonged treatment with orlistat.
- Patients should be advised about the potential for rare but severe liver injury.
- Signs and symptoms such as pruritus, yellow eyes or skin (jaundice), dark urine, light-colored stools, anorexia, or severe upper abdominal pain necessitate immediate discontinuation of orlistat and medical evaluation.
- Acute oxalate nephropathy, sometimes leading to renal failure, has also been reported, particularly in individuals with pre-existing chronic kidney disease; adequate hydration and renal function monitoring are recommended.
- Orlistat significantly reduces the absorption of fat-soluble vitamins (A, D, E, K) and beta-carotene, requiring daily supplementation taken at least two hours apart from orlistat.
- Caution is advised in patients with chronic malabsorption syndrome or cholestasis, as orlistat is contraindicated in these conditions.
- Drug interactions are also a concern: orlistat can decrease the absorption of ciclosporine, levothyroxine, and amiodarone, necessitating careful monitoring and dosage adjustments.
- Close monitoring of International Normalized Ratio (INR) is essential for patients on warfarin or other oral anticoagulants due to potential vitamin K malabsorption.
- In cases of severe diarrhea, the effectiveness of oral contraceptives may be reduced, and an additional contraceptive method should be considered.
How it Works (Mechanism of Action)
Orlistat exerts its therapeutic effect by reversibly inhibiting gastrointestinal lipases, specifically pancreatic and gastric lipases. These key enzymes are responsible for hydrolyzing dietary triglycerides into absorbable free fatty acids and monoglycerides within the lumen of the small intestine. By binding covalently to the active site of these lipases, orlistat forms an inactive complex, thereby preventing the breakdown and subsequent absorption of approximately 30% of dietary fat ingested at the recommended therapeutic dose. The undigested fat is then excreted in the feces. This reduction in caloric absorption from dietary fat leads to a negative energy balance, which contributes to weight loss and helps in preventing weight regain. Orlistat acts locally within the gastrointestinal tract, with minimal systemic absorption.